Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Vivek Garipalli Biography and Net Worth

Co-Founder of Clover Health Investments

Vivek Garipalli is the co-founder and CEO of Clover Health. Prior to founding Clover, he founded CarePoint Health in 2008, a fully integrated healthcare system in New Jersey. Through his role at CarePoint – whose mission is to serve uninsured and underinsured patient populations – Vivek experienced the misalignment of providers and insurance companies first-hand, which led to the founding of Clover. Vivek also co-founded a healthcare services revenue cycle company called Ensemble Health before teaming up with a couple of friends at Flatiron Health. He helped drive the development of Flatiron Health’s strategy and business model and sat on the board through its sale to Roche in 2018. Vivek is active in health tech, serving as a board member of Doctor Evidence and Medically Home and an investor in numerous early-stage health tech companies. The main cause he is focused on is helping with homelessness and is a financial supporter of The Bowery Mission in New York City and Newark, NJ. Vivek began his career in finance, holding roles at Credit Suisse First Boston, J.P. Morgan Partners and Blackstone Group. He earned a B.B.A. in Entrepreneurship from Emory University.

How old is Vivek Garipalli?: Mr. Garipalli is currently 45 years old. There are 5 older executives and no younger executives at Clover Health Investments. The oldest executive at Clover Health Investments is Ms. Jamie L. Reynoso, Chief Executive Officer of Medicare Advantage, who is 54 years old. Learn More on Vivek Garipalli's age.
How do I contact Vivek Garipalli?: The corporate mailing address for Mr. Garipalli and other Clover Health Investments executives is 317 University Ave Suite 200, Palo Alto CA, 94301. Clover Health Investments can also be reached via phone at 201-432-2133 and via email at [email protected]. Learn More on Vivek Garipalli's contact information.
Has Vivek Garipalli been buying or selling shares of Clover Health Investments?: Vivek Garipalli has not been actively trading shares of Clover Health Investments in the last ninety days. Learn More on Vivek Garipalli's trading history.
Who are Clover Health Investments' active insiders?: Clover Health Investments' insider roster includes Chelsea Clinton (Director), Vivek Garipalli (Co-Founder), and Chamath Palihapitiya (Major Shareholder). Learn More on Clover Health Investments' active insiders.
Are insiders buying or selling shares of Clover Health Investments?: During the last year, Clover Health Investments insiders bought shares 2 times. They purchased a total of 154,085 shares worth more than $116,411.60. The most recent insider tranaction occured on May, 16th when Director Anna U Loengard bought 17,085 shares worth more than $16,401.60. Insiders at Clover Health Investments own 22.3% of the company. Learn More about insider trades at Clover Health Investments.
Information on this page was last updated on 5/16/2024.

Vivek Garipalli Insider Trading History at Clover Health Investments

Vivek Garipalli Buying and Selling Activity at Clover Health Investments

Clover Health Investments Company Overview

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.

Today's Range

Now: $3.39

$3.28

$3.40

50 Day Range

MA: $3.57

$2.77

$4.35

2 Week Range

Now: $3.39

$0.61

$4.71

Volume

1,642,348 shs

Average Volume

8,019,079 shs

Market Capitalization

$1.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03

Trump won. Buy this coin now.

From Weiss Ratings | Ad